checklist: &id001
- Title and Abstract:
  - 1a_title.md
  - 1b_abstract.md
- Open Science:
  - 2_trial_registration.md
  - 3_protocol_and_statistical_analysis_plan.md
  - 4_data_sharing.md
  - 5. Funding and Conflicts of Interest:
    - 5a_funding.md
    - 5b_conflicts_of_interest.md
- Introduction:
  - 6_background_and_rationale.md
  - 7_objectives.md
- Methods:
  - 8_patient_and_public_involvement.md
  - 9_trial_design.md
  - 10_changes_to_trial_protocol.md
  - 11_trial_setting.md
  - 12. Eligibility Criteria:
    - 12a_eligibility_criteria_for_participants.md
    - 12b_eligibility_criteria_for_sites_and_individuals.md
  - 13_intervention_and_comparator.md
  - 14_outcomes.md
  - 15_harms.md
  - 16. Sample Size:
    - 16a_how_sample_size_was_determined.md
    - 16b_interim_analyses_and_stopping_criteria.md
  - 17. Randomisation:
    - 17a_sequence_generation.md
    - 17b_type_of_randomisation.md
  - 18_allocation_concealment_mechanism.md
  - 19_implementation.md
  - 20. Blinding:
    - 20a_who_was_blinded.md
    - 20b_how_was_blinding_achieved.md
  - 21. Statistical methods:
    - 21a.md
    - 21b.md
    - 21c.md
    - 21d.md
  - 22. Participant flow, including flow diagram:
    - 22a.md
    - 22b.md
  - 23. Recruitment:
    - 23a.md
    - 23b.md
  - 24. Intervention and comparator delivery:
    - 24a.md
    - 24b.md
  - 25_baseline_data.md
  - 26_numbers_analysed_outcomes_and_estimation.md
  - 27_harms.md
  - 28_ancillary_analyses.md
Discussion:
  - 29_interpretation.md
  - 30_limitations.md
web: *id001
